Table 10.
Association of PSRC1, CELSR2, and SORT1 SNPs with Warfarin Responsiveness During the Initiation Phase of Therapy of 212 Cardiovascular Patients Treated with Warfarin
| Gene | SNP ID | Genotype | Poora (n= 39) | Goodb (n= 162) | Ultrac (n= 11) | Overall P-value* |
|---|---|---|---|---|---|---|
| PSRC1 | rs646776 | CC | (4/11) 36.4% | (7/11) 63.6% | (0/11) 0.0% | 0.264 |
| P-value* | 0.11 | 0.31 | 0.43 | |||
| CT | (7/61) 11.5% | (51/61) 83.6% | (3/61) 4.9% | |||
| P-value* | 0.10 | 0.12 | 0.92 | |||
| TT | (28/140) 20% | (104/140) 74.3% | (8/140) 5.7% | |||
| P-value* | 0.40 | 0.31 | 0.63 | |||
| CELSR2 | rs660240 | CC | (28/139) 20.1% | (103/139) 94.1% | (8/139) 5.8% | 0.323 |
| P-value* | 0.48 | 0.37 | 0.69 | |||
| TC | (7/58) 12% | (48/58) 82.8% | (3/58) 5.2% | |||
| P-value* | 0.13 | 0.16 | 1 | |||
| TT | (4/11) 36.4% | (7/11) 63.6% | (0/11) 0.0% | |||
| P-value* | 0.13 | 0.32 | 0.42 | |||
| rs12740374 |
GG | (28/145) 19.3% | (109/145) 75.2% | (8/145) 5.5% | 0.646 | |
| P-value* | 0.65 | 0.31 | 0.24 | |||
| GT | (8/57) 14% | (46/57) 80.7% | (3/57) 5.3% | |||
| P-value* | 0.57 | 0.36 | 0.49 | |||
| TT | (3/9) 33.3% | (6/9) 66.7% | (0/9) 0.0% | |||
| P-value* | 0.76 | 1 | 0.47 | |||
| SORT1 | rs602633 | GG | (27/131) 20.6% | (97/131) 74% | (7/131) 5.3% | 0.196 |
| P-value* | 0.32 | 0.23 | 0.62 | |||
| GT | (7/65) 10.8% | (55/65) 84.6% | (3/65) 4.6% | |||
| P-value* | 0.06 | 0.07 | 0.32 | |||
| TT | (5/15) 33.3% | (10/15) 66.7% | (0/15) 0.0% | |||
| P-value* | 0.13 | 0.32 | 0.37 |
Notes: *Chi-square test with p< 0.05 is considered significant. a Poor responders (international normalized ratio (INR) value below target). b Good responders who have an INR in the target range (therapeutic range). cUltra-responders (INR over target).